KRAS and neoplasm: Multiple studies have reported that the mutation spectrum of bile cfDNA (such as TP53, KRAS, IDH1) is highly consistent with that in tumor tissue (P < 0.001) (Shen et al., 2019; Arechederra et al., 2022; Yin et al., 2024).